维生素D对精神分裂症患者抗精神病药暴露的负面影响可能抵消其潜在获益
该非干预性研究纳入80例精神分裂症患者,获取107份抗精神病药血清浓度、80份维生素D浓度及精神病理学评估。结果显示维生素D与剂量校正后抗精神病药浓度呈负相关,尤以主要经CYP3A4代谢的药物(阿立哌唑、喹硫平)为著;路径分析提示维生素D对症状有缓解作用,但被其对药物浓度的负面影响所抵消。
要点
- 维生素D水平与剂量校正后抗精神病药浓度呈负相关,CYP3A4代谢药物更明显
- 维生素D对症状的缓解作用被其降低药物浓度的效应所抵消
- 维生素D水平高于中位数的患者中阿立哌唑和喹硫平剂量归一化浓度治疗不足比例更高
核心结论
- 尽管维生素D对身心健康有潜在获益,临床医生应知晓其对CYP3A4代谢抗精神病药血药浓度的负面影响。
- 考虑补充维生素D时,应进行治疗药物监测以指导剂量调整。
研究设计与样本
- 非干预性研究,纳入80例精神分裂症患者,获取107份不同抗精神病药血清浓度、80份维生素D血清浓度及精神病理学评估。
- 采用广义线性模型、路径分析和相关性分析评估维生素D对抗精神病药浓度和症状学的影响。
主要发现
- 维生素D与剂量校正后抗精神病药浓度呈负相关,对主要经CYP3A4代谢的药物(阿立哌唑和喹硫平)尤为明显。
- 路径分析提示维生素D对症状有缓解作用,但被其对药物浓度的负面影响所抵消。
- 维生素D水平高于中位数的患者中,阿立哌唑和喹硫平剂量归一化浓度治疗不足的比例显著更高。
关键数值与推荐
- 维生素D水平高于中位数的患者中,阿立哌唑和喹硫平剂量归一化浓度治疗不足的比例显著更高。
临床怎么用
- 对使用CYP3A4代谢抗精神病药(如阿立哌唑、喹硫平)的精神分裂症患者,补充维生素D时应监测血药浓度。
- 根据治疗药物监测结果调整抗精神病药剂量,避免因维生素D补充导致药物暴露不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients with schizophrenia frequently show insufficient vitamin D levels, which are associated with somatic comorbidity and may contribute to psychopathology. For many reasons, vitamin D supplementation may be indicated for this patient cohort. However, there is growing evidence for a vitamin D-mediated increase of drug metabolism by induction of cytochrome P450 (CYP) 3A4. Hence, this study aimed to assess vitamin D's impact on both antipsychotic drug concentrations and psychopathology in a non-interventional manner. METHODS: Totals of 107 serum concentrations of different antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine and risperidone), 80 serum concentrations of vitamin D and psychopathological assessments were obtained from 80 patients with schizophrenia. The impact of Vitamin D on antipsychotic drug concentrations and symptomatology was assessed using a generalized linear model, path and correlation analyses. RESULTS: We observed a negative relationship between vitamin D and dose-adjusted antipsychotic drug concentrations, which was particularly pronounced for drugs which are predominantly metabolized via CYP3A4 (i.e., aripiprazole and quetiapine). A path analysis suggested a relieving effect of vitamin D on symptomatology which was, however, counteracted by its negative impact on antipsychotic drug levels. Finally, patients with vitamin D levels above the median exhibited a significantly higher proportion of therapeutically insufficient dose-normalized drug concentrations of aripiprazole and quetiapine. CONCLUSION: Despite vitamin D's potential benefits on physical and mental health, clinicians should be aware of its negative impact on blood concentrations of antipsychotics metabolized by CYP3A4 in patients with schizophrenia. Therefore, when considering its supplementation, therapeutic drug monitoring should be applied to guide dose adjustment.
引用
- Gaebler AJ, Finner-Prével M, Lammertz S, et al. The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. Br J Clin Pharmacol. 2022. PMID: 35380747. doi:10.1111/bcp.15223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。